Back to Network
10
Shared Docs
10
Same-Page
27 / 10
Mentions
Document Mentions (10 shared documents)
6 mentions1 same-page
Page ?Same page
To: Jefffrey Epstein[[email protected]]; Rich Kahn From: Lesley Groff Sent: Thur 1/17/2019 5:19:49 PM Subject: Fo From: < r t oksjaySsam a > To: jeevacation@gmaitcom <jeevacat
neinmait.com>; I requested I forward you the below `catch up' email. Sent: Wednesday, January 16, 2019, 11:22:06 PM EST Subject: Catching Up Dear Jeffrey I hope you've been well. I wanted to update you on what I've been up to for the last two years. I was also hoping to talk with you to sec if I migh
16, 2019, 11:22:06 PM EST Subject: Catching Up Dear Jeffrey I hope you've been well. I wanted to update you
To: Jefffrey Epstein[[email protected]]; Rich Kahn From: Lesley
To: Jefffrey Epstein[[email protected]]; Rich Kahn From: Lesley
ical industry to shift their focus from addressing symptoms of disease to fundamental evolutionary shortfalls. So far, I placed a genetic vector at the National Institute of Medicine in France (that EFTA_R1_01089814 EFTA02275773 reversed glaucoma in mice using the neuroglobin gene) under formal licence review with a publicly
5 mentions1 same-page
Page ?Same page
From: Lesley Groff To: Jefffrey Epstein <[email protected]>, Rich Kahn < Subject: Date: Thu, 17 Jan 2019 17:19:49 +0000 Inline-Images: 1506365439123blobjpg; 1506365439123blob(1).jpg
e -- Forwarded Message --- From To: je . [email protected]>; Sent: Wednesday, January 16, 2019, 11:22:06 PM EST Subject: Catching Up Dear Jeffrey I hope you've been well. I wanted to update you on what I've been up to for the last two years. I was also hoping to talk with you to see if I migh
16, 2019, 11:22:06 PM EST Subject: Catching Up Dear Jeffrey I hope you've been well. I wanted to update you
From: Lesley Groff To: Jefffrey Epstein <[email protected]>, Rich Kahn < Subject: D
ical industry to shift their focus from addressing symptoms of disease to fundamental evolutionary shortfalls. So far, I placed a genetic vector at the National Institute of Medicine in France (that reversed glaucoma in mice using the neuroglobin gene) under formal licence review with a publicly traded pharma group here in the US
5 mentions1 same-page
Page ?Same page
From: Lesley Groff <-> Sent: Thursday, January 17, 2019 5:20 PM To: Jefffrey Epstein; Rich Kahn Subject: requested I forward you the below 'catch =p' email. = cell: <=ont =d="ydp10b69158yiv1803357833ydpcb0f5alfyiv3847271241ydp49
ion@ mail.com <mailto:•[email protected]> <[email protected]>; Sent: Wednesday, January 16, 2019, 11:22:06 PM =ST Subject: Catching =p Dear Jeffrey > > I hope you've been well. = wanted to update you on what I've been up to for the last two years. I =as also hoping to talk with you to see if I
16, 2019, 11:22:06 PM =ST Subject: Catching =p Dear Jeffrey > > I hope you've been well. = wanted to update
Thursday, January 17, 2019 5:20 PM To: Jefffrey Epstein; Rich Kahn Subject: requested I forward you the
ical industry to shift their focus from addressing =ymptoms of disease to fundamental evolutionary shortfalls. So far, I placed a =enetic vector at the National Institute of Medicine in France (that =eversed glaucoma in mice using the neuroglobin gene) under formal =icence review with a publicly traded pharma group here in the US
Sponsored
3 mentions1 same-page
Page ?Same page
well with you too. Lesley On Jan 17, 2019, at 12:09 PM ,. wrote: Hi Lesley, I hope you're well! It's been a while since I was in touch! I emailed Jeffrey and Rich last night but wasn't sure that they still use the email addresses that I have. Thank you for forwarding this onto to them if you can. I h
16, 2019, 11:22:06 PM EST Subject: Catching Up Dear Jeffrey I hope you've been well. I wanted to update you
ical industry to shift their focus from addressing symptoms of disease to fundamental evolutionary shortfalls. So far, I placed a genetic vector at the National Institute of Medicine in France (that reversed glaucoma in mice using the neuroglobin gene) under formal licence review with a publicly traded pharma group here in the US
3 mentions1 same-page
Page ?Same page
email: www.Mohebe.com @Bioliebe <1506365439123blobjpg> Fro To: Sent: Wednesday, January 16, 2019, 11:22:06 PM EST Subject: Catching Up Dear Jeffrey I hope you've been well. I wanted to update you on what I've been up to for the last two years. I was also hoping to talk with you to see if I migh
16, 2019, 11:22:06 PM EST Subject: Catching Up Dear Jeffrey I hope you've been well. I wanted to update you
ical industry to shift their focus from addressing symptoms of disease to fundamental evolutionary shortfalls. So far, I placed a genetic vector at the National Institute of Medicine in France (that reversed glaucoma in mice using the neuroglobin gene) under formal licence review with a publicly traded pharma group here in the U
3 mentions1 same-page
Page ?Same page
hthe.com <1506365439123b1ob.jpg> Forwarded Message Fro To: < >: Sent: Wednesday, January 16, 2019. 11:22:06 PM EST Subject: Catching Up Dear Jeffrey > > wrote: I hope you've been well. I wanted to update you on what I've been up to for the last two years. I was also hoping to talk with you to
16, 2019. 11:22:06 PM EST Subject: Catching Up Dear Jeffrey > > wrote: I hope you've been well. I wanted t
ical industry to shift their focus from addressing symptoms of disease to fundamental evolutionary shortfalls. So far, I placed a genetic vector at the National Institute of Medicine in France (that reversed glaucoma in mice using the neuroglobin gene) under formal licence review with a publicly traded pharma group here in the U
Sponsored
3 mentions1 same-page
Page ?Same page
To: m m From: Sent T Ur Subject Fw: Catching Up Hi Lesley, :48 PM I hope you're well! It's been a while since I was in touch! I emailed Jeffrey and Rich last night but wasn't sure that they still use the email addresses that I have. Thank you for forwarding this onto to them if you can. I
16, 2019, 11:22:06 PM EST Subject: Catching Up Dear Jeffrey I hope you've been well. I wanted to update you
ical industry to shift their focus from addressing symptoms of disease to fundamental evolutionary shortfalls. So far, I placed a genetic vector at the National Institute of Medicine in France (that reversed glaucoma in mice using the neuroglobin gene) under formal licence review with a publicly traded pharma group here in the U
3 mentions1 same-page
Page ?Same page
s well with you too. Lesley On Jan 17 2( . at :19 PMir wrote: Hi Lesley, I hope you're well! It's been a while since I was in touch! I emailed Jeffrey and Rich last night but wasn't sure that they still use the email addresses that I have. Thank you for forwarding this onto to them if you can. I
R1_01089429 EFTA02275605 Subject: Catching Up Dear Jeffrey I hope you've been well. I wanted to update you
ical industry to shift their focus from addressing symptoms of disease to fundamental evolutionary shortfalls. So far, I placed a genetic vector at the National Institute of Medicine in France (that reversed glaucoma in mice using the neuroglobin gene) under formal licence review with a publicly traded pharma group here in the U
3 mentions1 same-page
Page ?Same page
onAomail.com <jeevacabonOornail.com>; Sent: Wednesday, January 16, 2019, 11:22:06 PM EST EFTA_R1_01093559 EFTA02278036 Subject: Catching Up Dear Jeffrey I hope you've been well. I wanted to update you on what I've been up to for the last two years. I was also hoping to talk with you to see if I migh
R1_01093559 EFTA02278036 Subject: Catching Up Dear Jeffrey I hope you've been well. I wanted to update you
cal industry to shift their focus from addressing symptoms of disease to fundamental evolutionary shortfalls. So far, I placed a genetic vector at the National Institute of Medicine in France (that reversed glaucoma in mice using the neuroglobin gene) under formal licence review with a publicly traded pharma group here in the U
Sponsored
3 mentions1 same-page
Page ?Same page
FTA_R1_01093672 EFTA02278091 — Fo From: To: jeevacationCWnrr <am Sent: Wednesday, January 16. 2019, 11:22:06 PM EST Subject: Catching Up Dear Jeffrey I hope you've been well. I wanted to update you on what I've been up to for the last two years. I was also hoping to talk with you to see if I mig
16. 2019, 11:22:06 PM EST Subject: Catching Up Dear Jeffrey I hope you've been well. I wanted to update you
cal industry to shift their focus from addressing symptoms of disease to fundamental evolutionary shortfalls. So far, I placed a genetic vector at the National Institute of Medicine in France (that reversed glaucoma in mice using the ncuroglobin gene) under formal licence review with a publicly traded pharma group here in the
Sponsored
Mutual Connections (7)
Entities connected to both Jeffrey Epstein and the National Institute of Medicine
